Genmab A/S (GNMSF) Rating Lowered to Sell at Zacks Investment Research

Genmab A/S (OTCMKTS:GNMSF) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Friday.

According to Zacks, “Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. In addition, Genmab has developed UniBody, a new proprietary technology that creates a stable, smaller antibody format. Genmab has operations in Europe and the US. “

Genmab A/S (GNMSF) opened at 218.00 on Friday. The company has a 50-day moving average price of $218.51 and a 200-day moving average price of $204.01. Genmab A/S has a one year low of $158.25 and a one year high of $225.50. The stock has a market cap of $13.26 billion, a P/E ratio of 62.82 and a beta of 1.08.

WARNING: This news story was first posted by Transcript Daily and is owned by of Transcript Daily. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this news story can be accessed at https://transcriptdaily.com/2017/08/13/genmab-as-gnmsf-rating-lowered-to-sell-at-zacks-investment-research.html.

Get a free copy of the Zacks research report on Genmab A/S (GNMSF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply